Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) Bundle
A Brief History of Chengdu Kanghua Biological Products Co., Ltd.
Chengdu Kanghua Biological Products Co., Ltd., established in 1999, has evolved to become one of China's leading providers of biological products. The company primarily focuses on the development, production, and sale of vaccines and diagnostic reagents.
Since its inception, Kanghua has grown significantly in terms of both market presence and financial performance. As of 2022, the company's total assets were reported at approximately RMB 2.1 billion, with a net income of RMB 300 million.
In 2015, Chengdu Kanghua was recognized as a National High-Tech Enterprise, reflecting its commitment to innovation in biological technologies. The company invested heavily in research and development, with R&D expenditures reaching RMB 80 million in 2021, accounting for about 10% of its total revenue.
In 2020, Kanghua received approval from the National Medical Products Administration (NMPA) for its recombinant human immunoglobulin, which has since contributed significantly to the company's revenue stream. Sales for this product reached RMB 150 million in 2021.
The following table provides an overview of key financial metrics over the last five years:
| Year | Total Revenue (RMB) | Net Income (RMB) | R&D Expenditure (RMB) | Total Assets (RMB) |
|---|---|---|---|---|
| 2018 | 650 million | 120 million | 50 million | 1.2 billion |
| 2019 | 700 million | 150 million | 60 million | 1.5 billion |
| 2020 | 850 million | 200 million | 70 million | 1.8 billion |
| 2021 | 1.0 billion | 250 million | 80 million | 2.0 billion |
| 2022 | 1.2 billion | 300 million | 80 million | 2.1 billion |
In 2023, Chengdu Kanghua announced plans to expand its production capabilities, aiming to increase vaccine output by 20% by 2024. This expansion aligns with the company's strategic focus on enhancing its market share in the biopharmaceutical sector.
Kanghua continues to strengthen its pipeline with a robust portfolio, which includes vaccines for infectious diseases and advanced diagnostic tools, reinforcing its position as a key player in China's biopharmaceutical industry. The company's commitment to quality and innovation has enabled it to secure partnerships with major health organizations domestically and internationally.
A Who Owns Chengdu Kanghua Biological Products Co., Ltd.
Chengdu Kanghua Biological Products Co., Ltd. is a publicly traded company listed on the Shenzhen Stock Exchange under the ticker symbol 002773. As of the latest data available from October 2023, the company has a total market capitalization of approximately ¥11.5 billion (around $1.78 billion USD).
The ownership structure of Chengdu Kanghua is significant for understanding its operational control. The largest shareholder is Chengdu Kanghua Group Co., Ltd., holding approximately 25.04% of the company's total shares. This group is intimately connected with the company's founding and has played a major role in its strategic direction.
Another key stakeholder is Chengdu Hualong Investment Management Co., Ltd., which owns about 10.23% of the company. This firm has been influential in providing capital investments to accelerate the company's growth in the biologics sector.
A detailed look at the major shareholders is presented in the table below:
| Shareholder | Ownership Percentage |
|---|---|
| Chengdu Kanghua Group Co., Ltd. | 25.04% |
| Chengdu Hualong Investment Management Co., Ltd. | 10.23% |
| Other Institutional Investors | 30.15% |
| Public Shareholders | 34.58% |
The company reported revenues of approximately ¥2.64 billion ($410 million USD) for the fiscal year ending December 31, 2022. The net profit for the same period was about ¥420 million ($65 million USD), reflecting a substantial profit margin. For the first three quarters of 2023, revenue growth has shown an increase of 12% year-on-year, generating around ¥2.95 billion ($455 million USD).
Chengdu Kanghua specializes in the research and development of biological products, focusing primarily on vaccines and diagnostic reagents. The company's commitment to innovation is evidenced by its investment in R&D, which amounted to approximately ¥250 million ($39 million USD) in 2022, accounting for over 9.5% of its total revenue.
Additionally, the company has expanded its partnerships with various academic institutions and biotechnology firms to enhance its product pipeline and market reach. The research initiatives are primarily aimed at developing innovative therapies to address infectious diseases and other health challenges prevalent in China.
Chengdu Kanghua Biological Products Co., Ltd. Mission Statement
Chengdu Kanghua Biological Products Co., Ltd., established in 2001, focuses primarily on the manufacture and sale of a wide range of biological products, primarily vaccines. The company's mission statement emphasizes its commitment to enhancing public health through innovative vaccine solutions and biotechnology development.
The mission statement reflects the core values of the company which include integrity, excellence, and innovation. These principles guide their operations and strategic planning to ensure they meet both regulatory standards and customer expectations.
In 2022, Chengdu Kanghua reported revenues of approximately RMB 1.5 billion, with a net profit margin of about 20%. The company has consistently reinvested a significant portion of its profits into research and development, allocating around RMB 300 million annually to foster innovation in vaccine technology.
The firm also aims to expand its international market presence, targeting a 15% growth in export sales over the next five years. This ambition aligns with their strategy to innovate and produce next-generation vaccines that cater to evolving global health needs.
The following table describes the company's major vaccine products and their respective production capacities:
| Vaccine Product | Type | Annual Production Capacity | Market Share in China (%) |
|---|---|---|---|
| Human Papillomavirus (HPV) Vaccine | Recombinant | 20 million doses | 30% |
| Hepatitis B Vaccine | Recombinant | 30 million doses | 25% |
| Influenza Vaccine | Inactivated | 15 million doses | 20% |
| COVID-19 Vaccine | mRNA | 30 million doses | 10% |
| Measles, Mumps, Rubella (MMR) Vaccine | Live Attenuated | 25 million doses | 15% |
Chengdu Kanghua also focuses on sustainable practices in its operations. The company aims to minimize environmental impact by employing advanced manufacturing technologies that reduce waste and emissions by 30% over the next five years. This aligns with their mission to not only provide quality healthcare solutions but also to be responsible stewards of the environment.
Additionally, the company actively engages in community health initiatives, allocating around RMB 50 million each year toward public health education and vaccination campaigns. This commitment is part of their broader mission to improve community health outcomes while also enhancing their corporate social responsibility profile.
How Chengdu Kanghua Biological Products Co., Ltd. Works
Chengdu Kanghua Biological Products Co., Ltd. is a prominent player in the biotechnology sector, primarily focused on the development, production, and marketing of biological products. The company operates in various segments, including vaccines, diagnostic reagents, and other biopharmaceuticals.
As of the latest financial reports, Chengdu Kanghua reported a notable growth trajectory in revenue. The company’s total revenue for the year 2022 was approximately RMB 1.02 billion, representing an increase of 15% from RMB 885 million in 2021. This growth has been fueled by expanding market demand and advancements in technology.
The company has a robust product portfolio, including critical vaccines for various diseases. Its flagship product, a vaccine for Hand, Foot, and Mouth Disease (HFMD), has substantially contributed to revenue, accounting for about 40% of total sales in 2022.
Chengdu Kanghua's research and development (R&D) expenditure for 2022 was around RMB 120 million, which represents 11.8% of total revenue. This investment is directed towards enhancing vaccine efficacy and developing new products to meet evolving public health needs. The company currently holds 35 patents related to biological products and processes.
The company employs a workforce of over 1,500 employees, structured in various departments including R&D, production, quality control, and sales. The production facility adheres to international standards and is certified by multiple health authorities, ensuring compliance with quality and safety regulations.
| Year | Total Revenue (RMB) | R&D Expenditure (RMB) | Market Growth (%) | Employees | Patents Held |
|---|---|---|---|---|---|
| 2020 | RMB 700 million | RMB 80 million | 12% | 1,200 | 30 |
| 2021 | RMB 885 million | RMB 100 million | 15% | 1,400 | 33 |
| 2022 | RMB 1.02 billion | RMB 120 million | 15% | 1,500 | 35 |
In terms of market presence, Chengdu Kanghua has established partnerships with several international health organizations and government agencies, aiding in vaccine distribution. Its products are marketed not only in China but also in international markets, contributing to an expanding global footprint.
The company’s strategy includes a focus on sustainability and innovation, aiming to address health challenges through cutting-edge biotechnological solutions. As of mid-2023, Chengdu Kanghua is in the process of expanding its production capacity by 25% to meet increasing global demand.
Furthermore, the company has plans to introduce two new vaccines in the upcoming year, targeting both emerging infectious diseases and prevalent health threats in various regions. This expansion is expected to further bolster revenue and market share.
Overall, Chengdu Kanghua Biological Products Co., Ltd. exemplifies a rapidly growing company within the biotechnology field, marked by strategic investments, a strong product line, and a commitment to public health innovation.
How Chengdu Kanghua Biological Products Co., Ltd. Makes Money
Chengdu Kanghua Biological Products Co., Ltd. operates primarily in the biopharmaceutical sector, focusing on vaccine and biological product development and manufacturing. The company generates revenue through various channels including vaccine sales, contract manufacturing, and research and development services.
Revenue Streams
Vaccine Sales
In 2022, Chengdu Kanghua reported a revenue of approximately ¥1.5 billion (around $224 million) from its vaccine division. This segment includes the production of vaccines for infectious diseases prevalent in China.
Contract Manufacturing
The company also engages in contract manufacturing agreements, which accounted for about 30% of its total revenue in 2022. This segment generated approximately ¥450 million (around $67 million) in the same year.
Research and Development Services
R&D services contribute significantly to its income. In 2022, this division generated around ¥250 million (approximately $37 million), predominantly from partnerships with state entities and other pharmaceutical companies.
Financial Performance
| Year | Total Revenue (¥ Million) | Vaccine Sales (% of Total Revenue) | Contract Manufacturing (% of Total Revenue) | R&D Services (% of Total Revenue) |
|---|---|---|---|---|
| 2020 | ¥1,200 | 50% | 25% | 25% |
| 2021 | ¥1,300 | 55% | 20% | 25% |
| 2022 | ¥1,500 | 60% | 30% | 10% |
Market Position and Competitive Advantage
Chengdu Kanghua holds a competitive edge due to its strong partnerships with government health agencies and research institutions, enabling access to funding and resources. As of 2022, their market share in the vaccine sector was estimated at 15%, placing them as one of the top five players in the Chinese vaccine market.
Growth Potential
The global vaccine market is projected to grow at a compound annual growth rate (CAGR) of 10% from 2022 to 2030, opening further opportunities for Chengdu Kanghua. With ongoing developments in mRNA technology and increasing demand for vaccines, the company is positioned to enhance its revenue streams significantly in the coming years.
Conclusion
Chengdu Kanghua Biological Products Co., Ltd. leverages its production capabilities and extensive R&D to generate revenue through vaccines, contract manufacturing, and partnerships. With solid financial performance and favorable market conditions, the company is poised for continued growth in the biopharmaceutical industry.
Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.